<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the role of cyclooxygenase-2 in the development of ischemic tolerance induced by cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> against transient, focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> was continuously induced for 2 h with topical <z:chebi fb="0" ids="32588">KCl</z:chebi> (13+/-1 depolarizations/2 h) in male Wistar rats </plain></SENT>
<SENT sid="2" pm="."><plain>At 1, 2, 3, 4, and 5 days following recovery, the middle cerebral artery was transiently occluded for 120 min </plain></SENT>
<SENT sid="3" pm="."><plain>Four days later, the animals were killed and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was determined </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, cyclooxygenase-2 levels in the cerebral cortex and 15 deoxy-Delta(12, 14) PGJ2 levels in cerebrospinal fluid were determined at these times with Western blotting and immunoassay, respectively </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was reduced compared with non-cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> control animals (274.3+/-15.3 mm3) when cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> was performed 3 and 4 days before middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (163.9+/-14.2 mm3, 154.9+/-14.2 mm3) but not at 1, 2 and 5 days (280.4+/-17.3 mm3, 276.3+/-16.9 mm3 and 268.5+/-17.3 mm3) </plain></SENT>
<SENT sid="6" pm="."><plain>Cyclooxygenase-2 levels increased most dramatically starting at 2 days, peaked at 3 days, and started to return toward baseline at 4 days after cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>15 Deoxy-Delta(12, 14) PGJ2 levels increased from 134.7+/-83 pg/ml at baseline to 718+/-98 pg/ml at 3 days </plain></SENT>
<SENT sid="8" pm="."><plain>Administration of N-[2-cyclohexyloxy-4-nitrophenyl] methanesulphonamide (10 mg/kg, i.v.), a selective <z:chebi fb="0" ids="50629">cyclooxygenase-2 inhibitor</z:chebi>, at 1 h prior to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> preconditioned animals did not affect <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (162.6+/-62.1 mm3) </plain></SENT>
<SENT sid="9" pm="."><plain>However, administration of N-[2-cyclohexyloxy-4-nitrophenyl] methanesulphonamide given three times prior to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> prevented the reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume induced by cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> preconditioning (272.9+/-63.2 mm3) </plain></SENT>
<SENT sid="10" pm="."><plain>Administration of L-<z:chebi fb="13" ids="29785">nitro</z:chebi>-arginine <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (4 mg/kg, i.v.) prior to cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> blocked increases in cyclooxygenase-2 normally seen at 3 and 4 days </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that NO-mediated cyclooxygenase-2 upregulation by cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> protects the brain against ischemic damage </plain></SENT>
</text></document>